Costimulatory molecules as targets for the induction of transplantation tolerance

Nephrology Dialysis Transplantation

Volumn 14, Issue 2, 1999, Pages 322-332

  Alegre, Maria Luisa ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN RECOGNITION; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGENS; HUMANS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 0032894102     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.2.322     Document Type: Review

References (81)

1. Billingham RE, Brent L, Medawar PB. Activity acquired tolerance to foreign cells. Nature 1953; 172: 602-606
2. Matis LA. The molecular basis of T-cell specificity. Ann Rev Immunol 1990; 8: 65-82
3. Shimonkevitz R, Kappler J, Marrack P, Gray H. Antigen recognition by H-2-restricted T cells. Cell free antigen processing. J Exp Med 1983; 158: 303-316
4. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329: 506-512
5. Auchincloss H Jr. Sultan H. Antigen processing and presentation in transplantation. Curr Opin Immunol 1996; 8: 681-687
6. Jenkins MJ, Ashwell JD, Schwartz RH. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol 1988; 140: 3324-3330
7. Jenkins MK, Mueller D, Schwartz RH et al. Induction and maintenance of anergy in mature T cells. Adv Exp Med Biol 1991; 292: 167-176
8. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349-1356
9. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994; 15: 321-330
10. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulales T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991; 173: 721-730
11. Thompson CB, Lindsten T, Ledbetter JA et al. activation pathway regulates the prodution of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989; 86: 1333-1337
12. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokinc messenger RNA stability by a surface-mediated T cell activation pathway. Science 1989; 244: 339-343
13. Boise LH, Minn AJ, Noel PJ et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity 1995; 3: 87-98
14. Radvanyi LG, Shi Y, Vaziri H et al. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol 1996; 156: 1788-1798
15. Boise LH, Gonzalez-Garcia M, Postema CE et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993, 74: 597-608
16. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB1. Proc Natl Acad Sci USA 1990; 87: 5031-5035
17. Freeman GJ, Freeman AS, Segil JM, Lee G, Whitman if, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989; 143: 2714-2722
18. Freeman GJ, Gray GS, Gimmi CD et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 1991; 174: 625-631
19. Nabavi N, Freeman GJ, Gault A, Godfrey D, Nadler LM, Glimcher LH. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992; 360: 266-268
20. Valle A, Aubry JP, Durand I, Banchereau J. IL-4 and IL-2 upregulate the expression of antigen B7, the B cell counterstructure to T cell CD28: an amplification mechanism for T-B cell interactions. Im Immunol 1991; 3: 229-235
21. Freeman GJ, Gribben JG, Boussiotis VA et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993; 262: 909-911
22. Azuma M, Ito D, Yagita H et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993; 366: 76-79
23. Chen C, Gault A, Shen L, Nabavi N. Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule. J Immunol 1994; 152: 4929-4936
24. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Modes RJ. Comparative analysis ofB7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 1994; 180: 631-640
25. Brunet JF, Denizot F, Luciani MF et al. A new member of the immunoglobulin superfamily CTLA-4. Nature 1987; 328: 267-270
26. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413
27. Krummel ME, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465
28. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Ann Rev Immunol 1996; 14: 233-258
29. Leung HT, Bradshaw J, Cleaveland JS, Linsley PS. Cytotoxic T lymphocyte-associated molecule-4, a high avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. J Biol Chem 1995; 270: 25107-25114
30. Fargeas C, Truneh A, Reddy M, Hurle M, Sweet R, Sekaly R. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4. J Exp Med 1995; 182: 667-675
31. Chuang E, Alegre ML, Duckett CS, Noel PJ, Vander Eiden MG, Thompson CB. Interaction of CTLA-4 with the clathrin-associated protein APSO results in ligand-independent endocytosis that limits cell surface expression. J Immunol 1997; 159: 144-151
32. Shiratori T, Miyatake S, Ohno H et al. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity 1997; 6: 583-589
33. Zhang Y, Allison JP. Interaction of CTLA-4 with APSO, a clathrin-coated pit adaptor protein. Proc Natl Acad Sci USA 1997; 94: 9273-9278
34. Walunas TL, Bluestone JA. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol 1998; 160: 3855-3860
35. Leach DR, Krummel ME, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736
36. Luhder F, Hoglund P, Allison JP, Benoist C, Mathis D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 1998; 187: 427-432
37. Perrin PJ, Maldonado JH. Davis TA, June CH, Racke MK. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyclitis. J Immunol 1996; 157: 1333-1336
38. Lin H, Rathmell JC, Gray GS. Thompson CB, Leiden JM. Alegre ML. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice. CTLA4 can function independently of CD28. J Exp Med 1998; 188: 199-204
39. Krummel ME, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996; 183: 2533-2540
40. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 2541-2550
41. Blair PJ, Riley JL, Levine BL et al. CTLA-4 ligation delivers a unique signal to resting human CD4T cells that inhibits interleukin-2 secretion but allows Bcl-xL induction. J Immunol 1998; 160: 12-15
42. Tivol EA, Borriello F, Schweitzer AN, Lynch WP. Bluestone JA, Sharpe AH. Loss of CTLA4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA4. Immunity 1995; 3: 541-547
43. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270: 985-988
44. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997; 9: 641-647
45. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993; 177: 925-935
46. Caux C, Massacrier C, Vanbervliet B et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180: 1263-1272
47. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474-478
48. Bennett SRM, Carbone FR, Karamalis F, Flavell RA, Miller JFAP, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-480
49. Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM. T-cell help for cytotoxic T lymphocytes is mediated by CD40 CD40L interactions. Nature 1998; 393: 480-483
50. Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NE-kappa B by TNF receptor 2 and CD40. Science 1995; 269: 1424-1427
51. Wang Z, Karras JG, Howard HG, Rothstein TL. Induction of bcl-x by CD40 engagement rescues slg-induced apoptosis in murine B cells. J Immunol 1995; 155: 3722-3725
52. Liu Y, Jones B, Janeway CA, Linsley PS. Co-stimulalion of murine CD4 T cell growth: cooperation between B7 and heat-stable antigen. Eur J Immunol 1992; 22: 2855-2859
53. Pattison JM, Krensky AM. New insights into mechanisms of allograft rejection. Am J Med Sci 1997; 313: 257-263
54. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs, tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8: 710-720
55. Fields P, Fitch FW, Gajewski TF. Control of T lymphocyte signal transduction through clonal anergy. J Mol Med 1996; 73: 673-683
56. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol 1987; 7: 4472-4481
57. Rudd CE. Upstream-downstream: CD28 cosignaling pathways and T cell function. Immunity 1996; 4: 527-534
58. Klasen S, Pages F, Peyron J-F, Cantrell DA, Olive D. Two distinct regions of the CD28 intracytoplasmic domain are involved in the tyrosine phosphorylation of Vav and GTPase activating protein-associated p62 protein. Int Immunol 1998; 10: 481-489
59. Kaga S, Ragg S, Rogers KA, Ochi A. Activation of p2l-CDC42/Rac-activated kinases by CD28 signaling: p21-activated kinase (PAK) and MEK kinase 1 (MEKK1) may mediate the interplay between CD3 and CD28 signals. J Immunol 1998; 160: 4182-4189
60. Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 1994; 77: 727-736
61. Fallarino F, Fields PE, Gajewski TF. B7 1 engagement of cylotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J Immunol 1998; 188: 205-210
62. Revilla Calvo C, Amsen D, Kruisbeek AM. Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and jun NH2-terminal kinase (INK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70. J Exp Med 1997; 186: 1645-1653
63. Schneider H, Prasad KVS, Shoelson SE, Rudd CE. CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells. J Exp Med 1995; 181: 351-355
64. Marengere LE, Waterhouse P, Duncan GS, Mittrucker H-W, Feng G, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996; 272: 1170-1173
65. Miyatake S, Nakaseko C, Umemori H, Yamamoto T, Saito T. Src family tyrosine kinases associate with and phosphorylate CTLA-4 (CD 152). Biochem Biophys Res Commun 1998; 248: 444-448
66. Perez VL, van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997; 6: 411-417
67. Samoilova EB, Horton JL, Zhang H, Khoury SJ, Weiner HL, Chen Y. CTLA-4 is required for the induction of high dose oral tolerance. Int Immunol 1998; 10: 491-498
68. Turka LA, Linsley PS, Lin H et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102-11105
69. Lin H, Boiling SF, Linsley PS et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801-1806
70. Tran HM, Nickerson PW, Restifo AC et al. Distinct mechanisms for the induction and maintanance of allograft tolerance with CTLA4-Fc treatment. J Immunol 1997; 159: 2232-2239
71. Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA 1996; 93: 13967-13972
72. Larsen CP, Alexander DZ, Hollenbaugh D et al. CD40-gp39 interactions play a critical role during allograft rejection, suppression of allograft rejection by blockade of the CD40-gp39. pathway. Transplantation 1996; 61: 4-9
73. Parker DC, Greiner DL, Phillips NE et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995; 92: 9560-9564
74. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997; 9: 641-647
75. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-438
76. Kirk AD, Harlan DM, Armstrong NN et al. Costimulation blockade prevents rejection following primate renal allotransplantation. Proc Natl Acad Sci USA 1997; 94: 8780-8794
77. Orosz CG, Pelletier RP. Chronic remodeling pathology in grafts. Can Opin Immunol 1997; 9: 676-680
78. Russell ME, Hancock WW, Akalin E et al. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996; 97: 833-838
79. Azuma H, Chandraker A, Nadeau K et al. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci USA 1996; 93: 12439-12444
80. Sun H, Subbotin V, Chen C et al. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. Transplantation 1997; 64: 1838-1856
81. Chandraker A, Russell ME, Glysing-Jensen T, Willett TA, Sayegh MH. T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen. Transplantation 1997; 63: 1053-1058